(1) As used in this part:(1) “Anti-rejection drug” means a prescription drug that suppresses the immune system to prevent or reverse rejection of a transplanted organ;(2) “Board” means the board of pharmacy;(3) “Cancer drug” means a prescription drug that is used to treat:(A) Cancer or the side effects of cancer; or(B) The side effects of a prescription drug that is used to treat cancer or the side effects of cancer;(4) “Controlled substance” has the same meaning as defined in § 39-17-402;(5) “Department” means the department of health;(6) “Donor” means any of the following that donates prescription drugs to a repository program approved pursuant to this part:(A) A person;(B) A pharmacy;(C) A medical facility;(D) A drug manufacturer or wholesaler licensed by the board; or(E) A prison or government entity federally authorized to possess prescription drugs with a license or permit in good standing in the state in which the entity is located;(7) “Eligible individual” means an indigent, an uninsured person, or an underinsured person who meets the criteria for eligibility pursuant to this part;(8) “Indigent” means a person with an income that is below six hundred percent (600%) of the federal poverty level as defined by the most recently revised poverty income guidelines published by the United States department of health and human services;(9) “Medical facility” means:(A) A physician's office;(B) A hospital;(C) A health clinic;(D) A nonprofit health clinic, including a federally qualified health center as defined in 42 U.S.C. § 1396d(l)(2)(B); a rural health clinic, as defined in 42 U.S.C. § 1396d(l)(1); and a nonprofit health clinic that provides medical care to patients who are indigent, uninsured, or underinsured;(E) A free clinic as defined in § 63-6-703;(F) A charitable organization as defined in § 48-101-501; or(G) A nursing home as defined in § 68-11-201;(10) “Pharmacy” means a pharmacy as defined in § 63-10-204;(11) “Prescription drug”:(A) Has the same meaning as defined in § 63-10-204;(B) Includes, but is not limited to, cancer drugs and anti-rejection drugs; and(C) Does not include:(i) Controlled substances; or(ii) Drugs covered by the risk evaluation and mitigation strategy program of the United States food and drug administration;(12) “Repository” means a pharmacy that:(A) Has a license or permit in good standing with the board; and(B) Meets the requirements established by § 63-10-503;(13) “Supplies” means the supplies necessary to administer the prescription drugs donated pursuant to this part; and(14) “Unopened tamper-evident packaging” has the same meaning as defined in United States Pharmacopeia (USP) General Chapter 659, Packaging and Storage Requirements.
(1) “Anti-rejection drug” means a prescription drug that suppresses the immune system to prevent or reverse rejection of a transplanted organ;
(2) “Board” means the board of pharmacy;
(3) “Cancer drug” means a prescription drug that is used to treat:(A) Cancer or the side effects of cancer; or(B) The side effects of a prescription drug that is used to treat cancer or the side effects of cancer;
(A) Cancer or the side effects of cancer; or
(B) The side effects of a prescription drug that is used to treat cancer or the side effects of cancer;
(4) “Controlled substance” has the same meaning as defined in § 39-17-402;
(5) “Department” means the department of health;
(6) “Donor” means any of the following that donates prescription drugs to a repository program approved pursuant to this part:(A) A person;(B) A pharmacy;(C) A medical facility;(D) A drug manufacturer or wholesaler licensed by the board; or(E) A prison or government entity federally authorized to possess prescription drugs with a license or permit in good standing in the state in which the entity is located;
(A) A person;
(B) A pharmacy;
(C) A medical facility;
(D) A drug manufacturer or wholesaler licensed by the board; or
(E) A prison or government entity federally authorized to possess prescription drugs with a license or permit in good standing in the state in which the entity is located;
(7) “Eligible individual” means an indigent, an uninsured person, or an underinsured person who meets the criteria for eligibility pursuant to this part;
(8) “Indigent” means a person with an income that is below six hundred percent (600%) of the federal poverty level as defined by the most recently revised poverty income guidelines published by the United States department of health and human services;
(9) “Medical facility” means:(A) A physician's office;(B) A hospital;(C) A health clinic;(D) A nonprofit health clinic, including a federally qualified health center as defined in 42 U.S.C. § 1396d(l)(2)(B); a rural health clinic, as defined in 42 U.S.C. § 1396d(l)(1); and a nonprofit health clinic that provides medical care to patients who are indigent, uninsured, or underinsured;(E) A free clinic as defined in § 63-6-703;(F) A charitable organization as defined in § 48-101-501; or(G) A nursing home as defined in § 68-11-201;
(A) A physician's office;
(B) A hospital;
(C) A health clinic;
(D) A nonprofit health clinic, including a federally qualified health center as defined in 42 U.S.C. § 1396d(l)(2)(B); a rural health clinic, as defined in 42 U.S.C. § 1396d(l)(1); and a nonprofit health clinic that provides medical care to patients who are indigent, uninsured, or underinsured;
(E) A free clinic as defined in § 63-6-703;
(F) A charitable organization as defined in § 48-101-501; or
(G) A nursing home as defined in § 68-11-201;
(10) “Pharmacy” means a pharmacy as defined in § 63-10-204;
(11) “Prescription drug”:(A) Has the same meaning as defined in § 63-10-204;(B) Includes, but is not limited to, cancer drugs and anti-rejection drugs; and(C) Does not include:(i) Controlled substances; or(ii) Drugs covered by the risk evaluation and mitigation strategy program of the United States food and drug administration;
(A) Has the same meaning as defined in § 63-10-204;
(B) Includes, but is not limited to, cancer drugs and anti-rejection drugs; and
(C) Does not include:(i) Controlled substances; or(ii) Drugs covered by the risk evaluation and mitigation strategy program of the United States food and drug administration;
(i) Controlled substances; or
(ii) Drugs covered by the risk evaluation and mitigation strategy program of the United States food and drug administration;
(12) “Repository” means a pharmacy that:(A) Has a license or permit in good standing with the board; and(B) Meets the requirements established by § 63-10-503;
(A) Has a license or permit in good standing with the board; and
(B) Meets the requirements established by § 63-10-503;
(13) “Supplies” means the supplies necessary to administer the prescription drugs donated pursuant to this part; and
(14) “Unopened tamper-evident packaging” has the same meaning as defined in United States Pharmacopeia (USP) General Chapter 659, Packaging and Storage Requirements.